Compounds of Formula (1.0.0):
##STR1##
are described wherein A is for example aryl, heteroaryl or heterocyclyl, Y
is preferably --C(.dbd.O)--; B is independently selected from a group of
moieties, the most preferred of which are those of partial Formulas
(1.1.2) and (1.1.6):
##STR2##
and E is a single bond; oxygen; 1,1-cyclopropyl; C(CH.sub.3).sub.2 ;
CF.sub.2 ; or a bridging moiety of partial Formula (1.9.0):
##STR3##
where R.sup.1.sub.a is hydrogen when R.sup.1 has the meaning of a
mono-valent substituent; and R.sup.1.sub.a is a single bond when R.sup.1
has the meaning of a di-valent substituent. Said compounds are useful in
methods of treating or preventing an inflammatory, autoimmune or
respiratory diseases by inhibiting cell adhesion and consequent or
associated pathogenic processes subsequently mediated by VLA-4.